An investigator-initiated clinical study in patients with refractory or recurrent solid tumors: ‘R-ISV-FOLactis’ trial-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

An investigator-initiated clinical study in patients with refractory or recurrent solid tumors: ‘R-ISV-FOLactis’ trial

Published:2024-06-23 Issue:20 Volume:20 Page:1393-1400
ISSN:1479-6694
Container-title:Future Oncology
language:en
Short-container-title:Future Oncology

Author:

Dai Juanjuan¹^ORCID,Zhu Junmeng¹,Zhu Lijing¹,Wang Xiaolu¹,Bao Jinfeng¹,Chen Xinjie¹,Zhou Yingling¹,Min Limei¹,Qi Haoyue²,Liu Qin¹,Shen Jie¹,Tian Manman¹,Shao Jie¹,Li Rutian¹,Liu Baorui¹

Affiliation:

1. The Comprehensive Cancer Centre of Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China

2. Department of Oncology, Taikang Xianlin Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China

Funder

Nanjing Drum Tower Hospital

National Natural Science Foundation of China

Publisher

Informa UK Limited

Link

https://www.tandfonline.com/doi/pdf/10.1080/14796694.2024.2357063

Reference43 articles.

1. Combination regimens with PD-1/PD-L1 immune checkpoint inhibitors for gastrointestinal malignancies

2. Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations

3. The Extrinsic and Intrinsic Roles of PD-L1 and Its Receptor PD-1: Implications for Immunotherapy Treatment

4. Immunogenic Cell Death Induction by Ionizing Radiation

5. Whole Body Irradiation—Radiobiology or Medicine?

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP